| Category | Ampoule Skincare |
| Founded | 2018 |
| Headquarters | Jinan |
| Listing | Not separately listed; part of Bloomage (688363.SH) |
| Latest revenue | Parent Bloomage FY2025 revenue RMB 4.20bn |
| Hero SKUs | Anti-Acne Ampoule / 5D Hyaluronic Ampoule |
Brand History
Launched by Bloomage in 2018, QuadHA positioned itself as more efficacy-driven than Biohyalux: no basic hydration, but acne, anti-aging and repair — high-concentration actives with transparent ingredient lists. The Anti-Acne Ampoule broke out on social platforms with an acid-plus-hyaluronic combination.
As the ampoule space crowded, differentiation eroded. After 2023 the brand cut influencer spend, concentrated on Douyin self-broadcast and clinic channels, and added 5D hyaluronic and copper-peptide lines. In 2025, with Bloomage's skincare segment down 42.1%, QuadHA held scale on steady acne-care repurchase, though Bloomage no longer reports brand-level revenue.
Hero Products
Three-Year Financials
| Year | Revenue (RMB bn) | YoY | Net profit (RMB bn) |
|---|---|---|---|
| 2023 | 60.76 | -4.45% | 5.93 |
| 2024 | 53.71 | -11.6% | 1.74 |
| 2025 | 41.99 | -21.82% | 2.91 |
Brand-level：QuadHA's revenue is not separately disclosed. Trade media reported a scale near RMB 1bn in 2021; the company no longer reports by brand, so 2025 figures cannot be verified.
Source：Bloomage annual reports 2023-2025; trade media
Company Coverage
- 2025-12Acne segment gets crowded
More brands enter oily-skin care with salicylic and azelaic acid; QuadHA turns to clinics for credibility.
Source：Trade media - 2025-08Douyin self-broadcast share rises
Influencer distribution was cut in favour of owned livestreams.
Source：Trade media - 2024-10Copper peptide line launched
Targeting anti-aging and repair above RMB 300.
Source：Brand
Observation: QuadHA's 'ampoule plus efficacy' formula has gone from differentiator to industry default. With Biohyalux, Comfy and even international brands in single-use formats, QuadHA needs harder evidence — clinical data, physician endorsement or patented actives — rather than competing on concentration and price. Moving into clinics is right, but clinic turnover is far slower than livestreaming and will not fill the online gap quickly.